DUSP1 and hepatocellular carcinoma: In HCC cell lines, it was observed that miR-101 targeted dual specificity phosphatase 1 (DUSP1), inhibited TGF-β activation and enhanced the effect of sorafenib in HCC cells by potentiating macrophage modulation of the innate immune responses [102].